Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a publicly traded Healthcare sector company. As of May 21, 2026, AMRX trades at $12.45 with a market cap of $3.80B and a P/E ratio of 31.40. AMRX moved +3.39% today. Year to date, AMRX is -3.78%; over the trailing twelve months it is +64.82%. Its 52-week range spans $6.69 to $15.42. Analyst consensus is strong buy with an average price target of $17.25. Rallies surfaces AMRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own AMRX include Blackbarn Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Amneal Pharmaceuticals, Inc. Class A Common Stock.
| Metric | Value |
|---|---|
| Price | $12.45 |
| Market Cap | $3.80B |
| P/E Ratio | 31.40 |
| EPS | $0.39 |
| Dividend Yield | 0.00% |
| 52-Week High | $15.42 |
| 52-Week Low | $6.69 |
| Volume | 1.20M |
| Avg Volume | 0 |
| Revenue (TTM) | $3.05B |
| Net Income | $181.31M |
| Gross Margin | 38.66% |
5 analysts cover AMRX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.25.